PMID- 24747180
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20140526
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 83
DP  - 2014 Aug
TI  - Impact of in vivo chronic blockade of adenosine A2A receptors on the 
      BDNF-mediated facilitation of LTP.
PG  - 99-106
LID - S0028-3908(14)00132-4 [pii]
LID - 10.1016/j.neuropharm.2014.04.006 [doi]
AB  - Brain-derived neurotrophic factor (BDNF) through the activation of its receptor 
      (TrkB-FL) exert well-described neuroprotective effects playing a major role in 
      hippocampal synaptic transmission and plasticity such as long-term potentiation 
      (LTP), a molecular surrogate for learning and memory. Impairments in BDNF 
      signalling have been associated to several neurodegenerative disorders such as 
      Alzheimer's disease (AD). Therefore, the reestablishment of BDNF actions is 
      considered a promising strategy for AD treatment. While, most of BDNF synaptic 
      actions, namely on LTP, require the activation of adenosine A2A receptor (A2AR), 
      the antagonists of A2AR have been proven to prevent AD induced deficits in 
      different animal models. Therefore in this work we aimed to evaluate the impact 
      of a chronic in vivo oral administration of an A2AR antagonist (KW-6002) in the 
      BDNF actions upon hippocampal CA1 LTP. The results showed that chronic blockade 
      of A2AR in male Wistar rats inhibits the facilitatory action of BDNF upon LTP on 
      hippocampal CA1 area and decreases both mRNA and protein levels of the TrkB-FL 
      receptor in hippocampus. These findings imply that BDNF signalling may be 
      affected in chronic A2AR blocking conditions.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Jeronimo-Santos, Andre
AU  - Jeronimo-Santos A
AD  - Instituto de Farmacologia e Neurociencias, Faculdade de Medicina, Universidade de 
      Lisboa, Portugal; Instituto de Medicina Molecular, Universidade de Lisboa, 
      Portugal.
FAU - Batalha, Vania L
AU  - Batalha VL
AD  - Instituto de Medicina Molecular, Universidade de Lisboa, Portugal.
FAU - Muller, Christa E
AU  - Muller CE
AD  - PharmaCenter Bonn, Pharmazeutische Chemie I, Pharmazeutisches Institut, 
      University of Bonn, Bonn, Germany.
FAU - Baqi, Younis
AU  - Baqi Y
AD  - PharmaCenter Bonn, Pharmazeutische Chemie I, Pharmazeutisches Institut, 
      University of Bonn, Bonn, Germany; Sultan Qaboos University, Department of 
      Chemistry, Faculty of Science, Muscat, Oman.
FAU - Sebastiao, Ana Maria
AU  - Sebastiao AM
AD  - Instituto de Farmacologia e Neurociencias, Faculdade de Medicina, Universidade de 
      Lisboa, Portugal; Instituto de Medicina Molecular, Universidade de Lisboa, 
      Portugal.
FAU - Lopes, Luisa V
AU  - Lopes LV
AD  - Instituto de Medicina Molecular, Universidade de Lisboa, Portugal.
FAU - Diogenes, Maria Jose
AU  - Diogenes MJ
AD  - Instituto de Farmacologia e Neurociencias, Faculdade de Medicina, Universidade de 
      Lisboa, Portugal; Instituto de Medicina Molecular, Universidade de Lisboa, 
      Portugal. Electronic address: diogenes@fm.ul.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140418
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Adenosine A2 Receptor Antagonists)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Purines)
RN  - 0 (Receptor, Adenosine A2A)
RN  - 2GZ0LIK7T4 (istradefylline)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Adenosine A2 Receptor Antagonists/pharmacology
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - CA1 Region, Hippocampal/drug effects/*metabolism
MH  - *Long-Term Potentiation/drug effects
MH  - Male
MH  - Purines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Adenosine A2A/*metabolism
MH  - Receptor, trkB/*metabolism
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Istradefylline
OT  - KW-6002
OT  - TrkB
EDAT- 2014/04/22 06:00
MHDA- 2015/01/30 06:00
CRDT- 2014/04/22 06:00
PHST- 2013/12/18 00:00 [received]
PHST- 2014/03/20 00:00 [revised]
PHST- 2014/04/08 00:00 [accepted]
PHST- 2014/04/22 06:00 [entrez]
PHST- 2014/04/22 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
AID - S0028-3908(14)00132-4 [pii]
AID - 10.1016/j.neuropharm.2014.04.006 [doi]
PST - ppublish
SO  - Neuropharmacology. 2014 Aug;83:99-106. doi: 10.1016/j.neuropharm.2014.04.006. 
      Epub 2014 Apr 18.